Global Ganja Report

Over the past two years, the Latin American cannabis industry has "emerged from the shadows" to command the attention of international firms and investors. Legal cannabis sales within the region are on track to reach $125 million in 2018—but that figure is expected to rise to $12.7 billion by 2028.

After years of upholding employee firings for use of cannabis even under state medical marijuana programs, the courts are finally starting to turn around on the question.

One of the ways state medical marijuana programs have failed to fully extend protection to medicinal users is in failure to defend against employment discrimination. This is now beginning to change, thanks to a few recent court decisions in favor of patients and employees.

The woman behind the South American nation's new medical marijuana law may yet face prison time. Her crime? Providing the only medicine that worked for her ailing son.

In the working-class Lima district of Pueblo Libre, I make my way to an apartment complex and up to the flat of Ana Álvarez—the unlikely woman almost singly responsible for Peru’s groundbreaking new medical marijuana law.

In a bedroom, 18-year-old Anthony watches a noisy Spiderman movie, occasionally interrupting through the open door as I chat with his mom in the living room. Anthony suffers from tuberous sclerosis, a severe form of epilepsy, and was the voiceless central figure behind the events that led to a major reform of Peru’s drug laws in 2017.

Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.

Among several cannabis-related bills signed into law by California's Gov. Jerry Brown was one creating an "equity" program for the state's legalized industry, aimed at justice and inclusion for those communities hardest hit by marijuana prohibition. Another measure will erase past convictions for possession of cannabis in quantities that are now legal.

With the DEA's rescheduling of Epidiolex, shares in the British manufacturer of the drug are soaring. But CBD—the actual cannabinoid that the product is based on—is to remain in the restrictive Scheudle 1.

As the UN General Assembly met in New York, President Trump issued a "Global Call" to renew the war on drugs—to the dismay of activists and dissenting nations. But the UN itself has a contradictory cannabis policy—with some agencies recognizing its efficacy as medicine and others backing the prohibitionist doctrine of the Single Convention treaty.

The Northern Mariana Islands, a self-governing commonwealth in association with the United States, just became first US territory to legalize adult-use cannabis. It is also the second US jurisdiction (after Vermont this January) to do so by legislation rather than popular ballot.